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Abstract
In vivo 13C magnetic resonance spectroscopy (MRS) enables the investigation of cerebral metabolic compartmentation
while, e.g. infusing 13C-labeled glucose. Metabolic flux analysis of 13C turnover previously yielded quantitative information
of glutamate and glutamine metabolism in humans and rats, while the application to in vivo mouse brain remains
exceedingly challenging. In the present study, 13C direct detection at 14.1 T provided highly resolved in vivo spectra
of the mouse brain while infusing [1,6-13C2]glucose for up to 5 h.
13C incorporation to glutamate and glutamine C4, C3,
and C2 and aspartate C3 were detected dynamically and fitted to a two-compartment model: flux estimation of neuron-
glial metabolism included tricarboxylic acid cycle (TCA) flux in astrocytes (Vg¼ 0.16 0.03 mmol/g/min) and neurons
(VTCA
n¼ 0.56 0.03 mmol/g/min), pyruvate carboxylase activity (VPC¼ 0.041 0.003 mmol/g/min) and neurotransmis-
sion rate (VNT¼ 0.084 0.008 mmol/g/min), resulting in a cerebral metabolic rate of glucose (CMRglc) of
0.38 0.02mmol/g/min, in excellent agreement with that determined with concomitant 18F-fluorodeoxyglucose positron
emission tomography (18FDG PET).We conclude that modeling of neuron-glial metabolism in vivo is accessible in the
mouse brain from 13C direct detection with an unprecedented spatial resolution under [1,6-13C2]glucose infusion.
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Introduction
13C magnetic resonance spectroscopy (MRS) is a
powerful tool that enables direct measurement of
brain metabolic ﬂuxes in vivo in humans and in
animal models. The low natural abundance of the 13C
isotope (1.1%) has been exploited by infusing
13C-labeled substrates, used as tracers, to explore the
metabolic fate of the substrate through metabolic path-
ways of interest by measuring the progressive labeling
of the downstream metabolic products. Speciﬁcally,
given the central role of glucose (Glc) in brain ener-
getics, [1-13C]glucose and [1,6-13C2]glucose have been
used to assess brain metabolism and neurotransmission
mainly through the measurement of the progressive
enrichment of glutamate (Glu) and glutamine (Gln) in
the positions C4, C3, and C2.1–3 From the separate
detection of Glu and Gln 13C peaks, it is possible to
assess the rate of the tricarboxylic acid (TCA) cycle,
the pyruvate carboxylase pathway (PC), the Glu and
Gln cycle through neurotransmission, and the exchange
between 2-oxoglutarate (OG) and Glu.
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Alternatively, brain glucose metabolism can be mea-
sured with 18F–ﬂuorodeoxyglucose positron emission
tomography (18FDG PET) allowing the determination
of local cerebral metabolic rate of glucose (CMRglc).
The use of 18FDG in vivo enables the local estimation
of total glucose consumption in oxidative and non-
oxidative pathways, however without details on further
steps in those biochemical pathways, since it does not
provide distinction between diﬀerent labelled metabolic
products (chemical speciﬁcity). This extension is made
possible when using NMR spectroscopy with introduc-
tion of stable isotopes, in particular 13C MRS.
Although in recent yearsmetabolicmodeling of in vivo
13CMRS data has been successful in describing the com-
partmentalized metabolism between neuronal and glial
cells,4–8 the applicability of highly detailed models is
often limited by the intrinsic low sensitivity of the tech-
nique, especially in small volumes, as it is the case for
mouse brain. Using direct detection of 13C nuclei, a
large number of 13C resonances are potentially accessible
since the wider chemical shift range associated with 13C
spectra compared to indirect detection via 1H nuclei
results in well resolved 13C peaks, however, at the cost
of a more signiﬁcant chemical shift displacement error.
Nevertheless, when taking advantage of the smaller 1H
chemical shift range to perform the localization in the 1H
channel, detection of broadband localized 13C MRS
in vivo spectra in the rat brain after infusion of
[1,6-13C2]glucose was shown to be feasible at 9.4 Tesla
by using 1H-localisation and a semi-adiabatic DEPT
sequence.9 Indirect 1H-[13C]MRS detection is an alterna-
tive that leads to an increased signal-to-noise ratio (SNR)
given the higher gyromagnetic ratio of 1H, however at the
expense of the smaller 1H chemical shift range, which
limits the distinct detection of Glu and Gln C3 and espe-
cially C27,10,11 resonances.
More recently, direct 13C detection and localization in
the 1H channel at ultra-high magnetic ﬁelds were com-
bined with a neuro-glial modeling scheme4 leading to an
extended characterization of the ﬂuxes related to energy
metabolism and neurotransmission between neurons and
glia in the rat brain.6 The separate detection of Glu and
Gln at the position C4 and C3 is the minimal prerequisite
to distinctly quantify cell-speciﬁc, i.e. astrocytes versus
neurons metabolism with minimal assumptions, as was
earlier shown for [1-13C] or [1,6-13C2]glucose infusion
protocols.12However, the inclusion of Glu andGln label-
ing in the position C2 is typically necessary for two-com-
partment modelling with minimal a priori constraints on
glial TCA cycle (Vg) and pyruvate carboxylase rate (VPC)
with infused 13C-labeled glucose. The addition of other
time courses such as aspartate (Asp) labelling generally
increases the robustness of the model.6,12 The separate
measurement of Asp, Glu and Gln at the position C2
remains only feasible through direct detection due to
the increased spectral dispersion especially at high mag-
netic ﬁelds. The importance of the inclusion of C3 and C2
Glu/Gln time courses in the modeling arises from the
inﬂuence of VPC in their progressive labeling: in fact,
this chemical reaction leads to labeling accumulation in
the position C2 of Glu and Gln while diluting the pos-
itions C3 from the incorporation of a 12C.
Besides the sensitivity limitation given by the small
volume of the mouse brain compared to larger rodents,
the experimental protocol brings additional challenges
given the diﬃculty in performing serial blood sampling
during the acquisition. Finally, the reduced size of brain
structures entails more pronounced magnetic susceptibil-
ity variations that will potentially aﬀect the linewidth and
consequently the SNR of the spectra. Nonetheless,
extending the application of 13C MRS to the study of
mouse brain and eventually applying metabolic modeling
could open the way to the characterization of brain
metabolism in diﬀerent animal models within genetically
engineered mice.
To our knowledge, in vivo 13C MRS in the mouse
brain was performed only once using direct detection
and infusion of [1,6-13C2]glucose,
13 however without
metabolic modelling interpretation, remaining other-
wise mainly limited to rat studies.5,6,14,15 In the present
study, we aimed to combine state of the art techniques
in 13C detection in the mouse brain with metabolic
modelling of such data for the quantiﬁcation of
neuro-glial ﬂuxes. High-quality 13C MRS spectra in
volumes as small as 112 mL were needed for the meas-
urement of turnover curves of Glu, Gln and Asp with
suﬃcient temporal resolution to be analyzed with a
two-compartment model of brain metabolism account-
ing for distinct neuronal and astrocytic metabolism.4
Minimal modelling assumptions resulted in a detailed
characterization of mouse brain metabolism. For this
purpose, a dedicated high sensitivity 13C/1H surface coil
for mice was designed and used in conjunction with
a semi-adiabatic polarization transfer sequence to over-
come the limitations given by RF ﬁeld inhomogeneity.
CMRglc values derived with PET upon
18FDG admin-
istration in the same brain region were used to provide
a cross-validation of the metabolic ﬂux analysis
obtained from 13C MRS metabolic modeling. The feasi-
bility of detailed in vivo dynamic 13C MRS in mice
potentially opens the way to its applicability to
a number of transgenic models available or in smaller
brain regions, reaching a new standard in spatial
resolution with 13C direct detection.
Materials and methods
All animal experimentation procedures were carried
out in compliance with the local ethical guidelines
(EXPANIM, Expe´rience sur animaux-SCAV, Service
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de la consommation et des aﬀaires ve´te´rinaires,
Switzerland) and approved by the Veterinary Oﬃce of
the Canton Vaud. Experimental procedures were
reported in compliance with the ARRIVE guidelines.
In vivo 13C NMR spectroscopy
Six male mice (Swiss NUDE, eight weeks old, 28–30 g,
Charles River, L’Arbresle Cedex, France) were used for
the 13C MRS experiments. The mice were housed in
ﬁlter-top cages, with a 12/12-h light-dark cycle, one
mouse per cage. Mice were provided with bedding
material, enrichment, and nesting material. They were
fasted overnight for 7 h with free access to water before
studies. Mice were anesthetized with isoﬂurane
(1–1.5%) for tail vein catheter insertion for substrate
administration. Respiration rate (100 bpm) was
monitored continuously during mouse anaesthesia
(SA Instruments Inc., NY, USA) and isoﬂurane level
adjusted accordingly. After surgical preparation, mice
were transferred in the magnet and placed in a home-
made holder that allows ﬁxing the head stereotactically
with the help of a bite bar/nose cone and ear rods
(Rapid Biomedical, Rimpar, Germany). Body tempera-
ture was kept stable (37.0–37.5C) with the use of a
circulating water hose and continuously monitored
using a home-built rectal temperature probe.
Experiments were performed in a 14.1 Tesla, 26-cm
horizontal bore magnet (Varian, Palo Alto,
CA/Magnex Scientiﬁc, Oxford, UK), using a home-
built 9-mm(13C)/15-mm(1H quad) surface coil as recei-
ver and transmitter. The magnet is equipped with
actively shielded gradients of (12-cm inner diameter,
Magnex Scientiﬁc, Oxford, UK) allowing a maximum
gradient strength of 400mT/m in 120 ms. An image
acquired with a fast spin-echo sequence was performed
in order to position the voxel (TR/TE¼ 5000/13ms,
FOV¼ 18 18mm, slice thickness 1mm, 4 averages).
Magnetic ﬁeld inhomogeneity was minimized by opti-
mizing ﬁrst and second-order shims with
FAST(EST)MAP16 (21–29Hz on localized water
peak). A 1H spectrum was collected in the same voxel
as for the dynamic 13C MRS prior to the adjustment of
13C MRS parameters and substrate injection, using
a short-TE localized SPECIAL sequence17 (TR/
TE¼ 4000/2.8ms) in order to obtain total metabolite
concentrations. Direct detection was achieved through
a semi-adiabatic DEPT polarization transfer sequence
(TR¼ 2.5 s, interpulse delay of 3.8ms (optimized for
JCH¼ 130Hz), 45 for the last 1H pulse for the simul-
taneous detection of CH, CH2, CH3 groups) combined
with 1H localization.9 A small sphere ﬁlled with 99%
13C-enriched formic acid was placed on the top of the
coil in order to provide a reference signal both for 13C
oﬀset frequency and B1 calibration in the
13C channel,
taking into account the changes in coil loading and
distance from the measured voxel to the coil. After
the calibration, the infusion protocol started with an
initial 5-min exponential bolus of 99% enriched
[1,6-13C2]glucose, followed by 5 h of continuous infu-
sion of 70% enriched [1,6-13C2]glucose (20% mass per
volume solution). The bolus volume per animal weight
was 4.01mL/kg; and the total volume of continuous
infusion was 1.99mL/kg/h. These bolus and continuous
infusion rates were established from bench experiments
and tail vein blood sampling, where the infusion rate
was varied in order to maintain glycemia levels
at 300mg/dL. Localized 13C spectra were acquired
from a volume of 112 mL (3.6  6.9  4.5 mm3) cover-
ing most of the brain but avoiding lipid contamination
from the scalp (Figure 2(c)). Spectra were acquired con-
tinuously over 5 h in blocks of 10.6min. Shimming was
repeated every 32min in order to keep the linewidth
constant.
Spectra quantiﬁcation of 1H and 13C spectra was per-
formed using LCModel.18 Normalization procedure of
spectra for absolute quantiﬁcation of 13C metabolite con-
centrations is described as Supplementary Information.
Normalization for RF eﬃciency on resonances at diﬀer-
ent frequency oﬀsets as well as for the diﬀerent eﬃciency
of the DEPT transfer for CH and CH2 groups was
achieved applying a correction factor derived from a nat-
ural abundance spectrum acquired on a phantom ﬁlled
with non-labeled compounds (Glu, Gln, Asp) and
scanned under identical experimental conditions.
18FDG positron emission tomography
2-Deoxy-2-18F-ﬂuoro-D-glucose (18FDG) was deliv-
ered to the CIBM from the commercial 18FDG produc-
tion facility at the Center for Radiopharmacy at
the University Hospital in Zurich, Switzerland.
18FDG was synthesized using aminopolyether sup-
ported nucleophilic ﬂuorination of the complex
1,3,4,6-tetra-O-acetyl-2-triﬂuor-methanesulfonyl-b-D-
mannopyranose (mannose triﬂate) as precursor, and
the aminopolyether potassium complex [K/2.2.2]þ18F
as phase-transfer catalyst. This process involved: (a) the
addition of mannose triﬂate into the 18F- with aceto-
nitrile; (b) hydrolysis to remove the protective acetyl
groups to form 18FDG; and (c) puriﬁcation of the
ﬁnal 18FDG product. The injectate was composed by
the following components: the active pharmaceutical
ingredient 18FDG, the nuclide [18F] Fluorine and the
pharmaceutical additives: NaH2PO4.2H2O (1.2mg/ml),
Na2HPO4.2H2O (4mg/ml), NaCl (7.5mg/ml), and
Na2S2O3.5H2O (1.3–1.9mg/ml).
Six healthy male NUDE mice (33.4–35.4 g) were
used for the PET experiments. Mice were anesthetized
for tail vein catheter insertion (25G home-made
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catheter). Initial values of glycemia were obtained at
the same time, prior to administration of 18FDG.
List-mode acquisitions were obtained with a single
ﬁeld of view centered on the body midsection, allowing
the inclusion of the brain and inferior vena cava, and
initiated with i.v. injection of 18FDG (1.6 0.3 MBq/g
body weight; meanSD; volume of injectate 50–
400 mL) through the tail vein catheter within the ﬁrst
10 s of the PET scan, followed by 100–150mL of saline
chase solution. Imaging was performed using an ava-
lanche photodiode micro-PET scanner (LabPET4,
GammaMedica, Sherbrook Canada). Mice were main-
tained under 1% isoﬂurane anaesthesia in oxygen deliv-
ered at 0.9L/min using a face mask with constant
monitoring of temperature and breathing rate. An
energy window of 250–650 keV and a coincidence
timing window of 22.2 ns were used for the detection
of photons at 511 keV resulting from annihilated
electron-positron pairs. For image reconstruction, a
built-in iterative maximum likelihood expectation max-
imum-based image (MLEM) reconstruction algorithm
was used in a cylindrical volume of 46mm in diameter
and 7 cm in length. Voxel size measured 0.5  0.5 
1.18 mm3, giving a typical resolution of <1.2mm at the
center of the FOV.
For temporal histogramming, the following time
frames (F) were used: 24F of 5 s duration; 6F of 30 s
duration; 5F of 2min duration; and 7F of 5min dur-
ation. All post-processing of images was performed
using PMOD 2.95 software (PMOD Technologies
Ltd, Switzerland).
The image-derived input function (IDIF) was deter-
mined from the time activity curves (TAC) of 18FDG in
the blood at the level of the inferior vena cava.19 Brieﬂy,
the volume of interest (VOI) drawn for the input func-
tion consisted in four adjacent regions of interest (1mm2
surface and 1.18mm thickness) in axial slices in corres-
pondence of the vena cava. Their location was estab-
lished based on visual inspection of the maximum
intensity projection image in the coronal plane where
the ﬂow of 18FDG was observed during the bolus. The
brain tissue TACs (tTACs) were selected frommid-brain
and were of the same volume and shape as the region
scanned during 13C MRS (Figure 5). The measured
radioactivity was corrected for the 18F radioactive
decay (relative to the start of the acquisition).
Metabolic modeling of 13C MRS data
13C MRS dynamic data were modelled following a
neuro-glial compartmentalized scheme, as previously
shown.4 Two-compartment scheme for glucose metab-
olism and label scrambling from [1,6-13C2]glucose into
the diﬀerent carbon positions of the measured amino
acids are summarized in Figure 1.
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Figure 1. (a) Two-compartmental model of neuro-glial metab-
olism in the brain used to describe 13C label transfer upon
[1,6-13C2]glucose infusion in the present study. Glucose is rapidly
taken up by brain tissue from the blood stream after passing
through the blood–brain barrier. Glycolysis converts it into
pyruvate (Pyr) which is not detectable in vivo due to its small
pool size. Given the rapid exchange between Pyr and lactate
(Lac) as compared to the TCA cycle flux, they are considered as
an indistinguishable pool that is in turn diluted by VLdil (inflow
from blood-borne lactate) and loses 13C label through Vout
(outflow towards blood). In both compartment, Pyr is converted
into acetyl-CoA (AcCoA), which is entering the TCA cycle. The
glial compartment is characterized by conversion of Pyr into
oxaloacetate (OAA) through pyruvate carboxylase (VPC) and by
glial specific substrates Vdil
g. Conversion of AcCoA in 2-oxoglu-
tarate (OG) leads to glutamate (Glu) synthesis in both com-
partments through the transmitochondrial flux Vx (VxþVPC in
the glial compartment). After a synaptic neurotransmitter
release, Glu is rapidly taken up from the synaptic cleft by glial
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The two-compartment scheme considers glucose as
the main brain energy substrate, where it is rapidly
transported from the blood stream through the
blood–brain barrier (BBB) into the cerebral tissue com-
partment. There, glycolysis metabolizes glucose into
pyruvate (Pyr) which is, in turn, in rapid exchange
with the lactate (Lac) pool through lactate dehydrogen-
ase (LDH) thereby converting labeling in C1 and C6
positions of glucose into C3 of Pyr and lactate. 13C
labeling is diluted at this node due to exchange with
blood lactate (VLdil). Moreover, the model accounts
for a small lactate eﬄux for contribution to non-
oxidative pathways (Vout). Label from Pyr ﬂows into
neuronal and glial TCA cycles: PC activity is essentially
localized in the glial compartment20 contributing to the
replenishment of TCA cycle intermediates, while inﬂux
of glial-speciﬁc substrates is considered through a dilu-
tion ﬂux at the level of Acetyl-CoA (AcCoA) in the glial
compartment6 (Vdil
g). Label at the level of AcCoA
ﬂows through the TCA cycle to 2OG that is in
exchange across the mitochondrial membrane with
Glu in both compartments. In the further part of the
TCA cycle, 13C can ﬂow alternatively from OG to
oxaloacetate (OAA) for further cycling. The glial
TCA cycle ﬂux VTCA
g is determined from mass-balance
considerations on the OG pool as the sum of the con-
version rate between OG and OAA (Vg) and VPC, while
neuronal TCA cycle (VTCA
n) corresponds to Pyr
dehydrogenase rate in neurons. In the glial compart-
ment, the forward conversion between OG and Glu
occurs at the rate VxþVPC, rather than Vx solely, due
to mass-balance considerations on the TCA intermedi-
ate pools. Glu synthetized in neurons is retained in pre-
synaptic vesicles, released in the synaptic cleft during
the glutamatergic neurotransmission process and
promptly taken-up by glial cells after postsynaptic
excitation to regulate extracellular Glu homeostasis.
Gln synthetase (VGS) synthetizes Gln from Glu specif-
ically in the glial compartment.21 Again, mass-balance
considerations on glial Glu and Gln lead to the equiva-
lence VGS¼VNTþVPC and the correspondence
Veﬄux¼VPC at metabolic steady-state. Finally, Gln
participates indirectly to neurotransmission by being
released in the extracellular space and subsequently
taken up by neurons, serving as precursor for Glu syn-
thesis and replenishment of neurotransmitter vesicles.
The transmitochondrial ﬂux Vx acts as exchange ﬂux
between OAA and Asp pools as well as between OG
and Glu in neurons in the malate-Asp shuttle.
The set of diﬀerential equations that characterize
the 13C labelling dynamics in the presented two-
compartment model was derived from the reaction
pathways in the neuronal and the glial compartments
as described above at metabolic steady-state (see
Supplementary Information). The input function was
generated as a step function with 70% glucose frac-
tional enrichment (FE).
13C time courses obtained from spectral quantiﬁca-
tion of individual animals were ﬁrst averaged over all
the subjects. The values of the metabolic ﬂuxes charac-
terizing the two-compartment model (Vtca
n, Vg, Vx,
VPC, VNT, Vdil
g, and Vout) were determined in a two-
step process. First, the set of diﬀerential equations was
at ﬁrst iteratively solved with a Runge–Kutta method
and solutions were ﬁtted to the measured 13C FE turn-
over curves by adjusting the metabolic ﬂux values
(regression parameters) using a Levenberg–Marquardt
algorithm for non-linear regression. FE curves were
weighted in the regression cost function by the inverse
of their variance, based on their respective noise level,
to avoid bias in the parameters regression. In the
second step, the precision of the estimated ﬂuxes was
determined by Monte Carlo (MC) simulation of the 13C
FE time courses (N¼ 300).22 Brieﬂy, after the estima-
tion of the metabolic ﬂuxes by the weighted regression
Figure 1. Continued
cells at an apparent neurotransmission rate (VNT), converted into
glutamine (Gln) through the action of glutamine synthetase (VGS)
and released in the extracellular space where it is mainly taken
back by neurons for conversion into Glu and refilling of the
neurotransmitter vesicles, completing the Glu/Gln cycle.
Alternatively, Gln is released in the extracellular space generating
a net efflux (Vefflux) which is compensated by de novo biosyn-
thesis of TCA cycle intermediates in the glial compartment
through VPC. Aspartate (Asp) labeling is essentially attributed to
the neuronal compartment from the direct exchange with OAA
through Vx in the malate/aspartate shuttle. (b)
13C labeling
scheme from [1,6-13C2]glucose (Glc1,6) metabolism through gly-
colysis and TCA cycle. Metabolites visible at steady-state in
typical in vivo scans are marked in bold. Glc1,6 leads to C3
labeling in pyruvate (Pyr3). Alanine transaminase (ALT) and lac-
tate dehydrogenase (LDH) regulate the labeling transfer to ala-
nine C3 (Ala3) and lactate C3 (Lac3), respectively. Alternatively,
Pyr3 labels the C4 position in 2-oxoglutarate (OG4) and glu-
tamate (Glu4) and consequently in glutamine (Gln4), through the
TCA cycle and further through glutamate/glutamine cycling.
Multiple turns of the TCA cycle (grey lines) eventually lead to a
progressive labeling of the positions C3 and C2 according to the
scheme. VPC (dashed line) brings additional labeling at the pos-
ition C2 as well as a dilution at the position C3 of OG, reflected
in glutamate and glutamine and representing a distinctive feature
for glial compartment TCA metabolism. GABA C4 (GABA4), C3
(GABA3), and C2 (GABA2) are synthetized from glutamate C2
(Glu2), C3 (Glu3), and C4 (Glu4), respectively, through
GABAergic neurotransmission (VGAD). The transmitochondrial
flux Vx regulates the exchange between oxaloacetate and aspar-
tate that will in turn label N-acetyl aspartate (NAA). Only the
positions C2 and C3 of aspartate (Asp2, Asp3) and NAA (NAA2,
NAA3) are visible in the observed chemical shift range. NAA is
also labeled at the position C6 (NAA6) from acetyl-CoA
(AcCoA2).
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method, the ﬂuxes were employed to generate a collec-
tion of noise-free 13C FE turnover curves, also used to
evaluate the noise level in each turnover curve by sub-
traction: N sets of artiﬁcial 13C turnover curves were
generated by adding N realizations of Gaussian noise
with corresponding noise level to the noise-free model
curves. A probability distribution for each metabolic
ﬂux is then obtained by ﬁtting the N sets of artiﬁcial
turnover curves. The standard deviation (SD) of each
distribution determines the uncertainty on the esti-
mated ﬂuxes.
Metabolic modeling of 18FDG kinetics in PET
experiments
The time activity curves of 18FDG acquired from the
blood and the brain over a 50min duration were pro-
cessed using Patlak graphical analysis,23 allowing an
estimation of CMRglc from the slope of the resulting
linear segment for each animal. The model predicts that
for a time t> t*, a linear relationship will be established
between
Ct ðtÞ
C
P
ðtÞ versus
R t
0
CPðsÞds
C
P
ðtÞ where C

PðtÞ represents the
plasma 18FDG radioactivity concentration (in kBq/ml)
at a given time t, and Ct ðtÞ the total tissue radioactivity
concentration. The slope of the linear ﬁtting curve is
equal to K* from which CMRglc is estimated as
CMRglc ¼ CP
LC
K ð1Þ
where CP is the plasma glucose concentration, and
LC is the lumped constant, ﬁxed to 0.625 for
mice.24,25 Plasma glucose is assumed to remain con-
stant throughout the PET scan, which is supported
by the fact that 18FDG is injected in pM concentra-
tions and it is presumed not to perturb glucose
homeostasis.
Biological systems can be studied with a Patlak ana-
lysis under the essential condition of irreversible trap-
ping of the tracer under study, meaning that once
18FDG is metabolized in the cell (i.e. it undergoes phos-
phorylation), de-phosphorylation is not possible
(k*4¼ 0). This assumption can be considered valid for
a scanning duration shorter than 27min in the mouse
brain.25–27 On the other hand, the time point t* deﬁnes
the time delay that is necessary to reach equilibrium in
FDG transport that will hence become unidirectional.
In the IF, t* is the time point characterized by a nearly
zero-slope in the curve after the bolus peak. Passed that
time, FDG radioactivity concentration in blood will
continue to decrease due to a combined eﬀect of
FDG uptake by major organs and muscles, as well as
kidneys and bladder (frequently referred to as product
loss). Speciﬁc t* of 5min was chosen to allow suﬃcient
time for reaching equilibrium in the exchange between
plasma and tissue compartment.
The complete equation for the Patlak regression
line is
Ct ðtÞ
CPðtÞ
¼ K
R t
0 C

PðsÞds
CPðtÞ
þ Vd ð2Þ
where Vd accounts for the non-zero intercept in the y
axis, which represents the initial volume of distribution.
Results
In vivo 13C MR spectra were obtained dynamically
from mouse brain in six animals for up to 5 h during
infusion of [1,6-13C2]glucose, in a volume of interest of
112 mL (Figure 2(c)). 13C MRS spectra acquired during
the ﬁrst 2.5 h with a temporal resolution of 10.6min
showed excellent sensitivity and spectral resolution in
the selected VOI, reaching an SNR of eight after only
160min (Figure 2(b)). GlcC6, LacC3 and GluC4 peaks
rose in magnitude from the ﬁrst 5min, reﬂecting a
prompt increase of blood glucose 13C level. Other
amino acid resonances were increasingly visible
during the ﬁrst hour (Figure 2(a)). Spectral resolution
was such that Glu and Gln peaks were well separated in
all carbon positions C4, C3, and C2.
Steady-state spectra acquired during 92min after
3.5 h of [1,6-13C2]glucose infusion, showed outstanding
SNR (>20) and spectral resolution (FWHM¼ 15Hz)
allowing detection of 17 distinct resonances
(Figure 3(a)) that account for a wide range of brain
metabolites involved in glucose glycolytic catabolism
and oxidation, synthesis of aminoacids and neurotrans-
mitters. GlcC6 was the ﬁrst peak to appear followed by
LacC3 (Figure 2(a)), labeled from PyrC3 as AlaC3
(Figure 1(b)). Although cerebral alanine (Ala) has a
relatively small pool size compared to Lac, AlaC3
became visible during the ﬁrst hour (Figure 2(a)) and
appeared clearly in steady-state spectra (Figure 3(a)).
GABA is the primary neurotransmitter involved in
inhibitory signaling and is directly synthetized by
GABAergic neurons from Glu. Therefore, label in pos-
itions C4, C3, and C2 of Glu is transferred to
GABAC2, C3, and C4, respectively, resulting in the
appearance of fairly prominent peaks given its rela-
tively large pool size in the striatum (3.1 0.2 mmol/g,
meanSD, as measured from the pre-infusion 1H
MRS scan). Asp is labeled from OAA through the Vx
exchange ﬂux (Figure 1(b)) in its four carbon positions.
However, only the C2 and C3 positions, namely at 53.2
and 37.4 ppm, fall within the detectable chemical shift
range. Finally, Asp acts as a precursor for NAA label-
ing in C2 and C3, while the C2 carbon of AcCoA is the
label precursor for NAAC6. NAA peaks in these three
1706 Journal of Cerebral Blood Flow & Metabolism
1520253035404550556065
ppm
5.2
15.8
26.3
38
48.5
59
72.5
83.1
93.5
106.5
117
127.6
140.4
150.9
Ti
m
e 
(m
in
)
161.3
G
lc
C6
G
lu
C2
G
ln
C2
G
A
BA
C2
G
lu
C4
G
ln
C4
G
lu
C3
G
ln
C3
La
cC
3
A
la
C3
A
sp
C3
A
sp
C2
G
A
BA
C4
 +
 N
A
AC
3
G
A
BA
C3
(c)
(b)
(a)
Figure 2. Typical 13C MRS spectra acquired at 14.1 Tesla in a volume of 112 mL and a time resolution of 10.2minutes. (a) Spectra
collected after the bolus of 99%-enriched [1,6-13C2]glucose and during continuous infusion for the first 150 mins with a temporal
resolution of 10.2min. Spectral SNR is enhanced by exponential apodisation (lb¼ 25Hz). (b) Spectrum acquired at 160min following
the bolus during 10.2minutes (SNR¼ 11; lb¼ 9Hz). (c) Three consecutive coronal slices (1mm thick) of a T2-weighted image
acquired prior to 13C MRS experiments showing voxel localization in the middle brain (3.6  6.9  4.5 mm3).
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positions were clearly detected in steady-state spectra
(Figure 3(a)). High spectral resolution allowed distinct
detection of multiplets at the position C3 and C4 of Glu
and Gln (Figure 3(b)). This feature allowed the calcu-
lation of the FE of GluC3 at steady-state and therefore
the rescaling of 13C concentrations in the spectra (see
Supplementary Information).
The fairly tight SD of the FE curves (Figure 4)
demonstrated high reproducibility between animals.
Maximal FE in GluC4 and GlnC4 reached 50% and
37%, respectively, at steady-state, while positions C3
were at 40% and 32%, respectively, indicating that
the latter were likely diluted by PC activity. The
lower FE of carbons C4 compared to glucose (70%)
is the direct consequence of the dilution ﬂux at the
level of the lactate pool (Vout) which will equally inﬂu-
ence Glu and Gln, while incorporation of glial-speciﬁc
substrates (Vdil
g) results mostly in the dilution of Gln
curves. Moreover, PC introduces additional labeling in
the positions C2 of Glu and Gln: this was observable
from a higher FE of 44% and 41% at steady-state,
respectively, compared to the C3 carbons.
Experimental curves of Glu C4, C3, and C2, Gln C4,
C3, and C2 and AspC3 were ﬁtted by the two-compart-
mental model for brain metabolism (Figure 1(a)). The
following metabolic ﬂuxes were determined (Table 1):
neuronal TCA cycle (VTCA
n¼ 0.56 0.03mmol/g/min),
glial TCA cycle (Vg¼ 0.16 0.03 mmol/g/min), PC
activity (VPC¼ 0.041 0.003 mmol/g/min), transmito-
chondrial ﬂux (Vx¼ 0.18 0.02 mmol/g/min), apparent
neurotransmission (VNT¼ 0.084 0.008mmol/g/min),
dilution in the Lac pool (Vout¼ 0.20 0.02 mmol/g/
min) due to non-oxidative utilization of glucose or
incorporation of other unlabeled substrates and dilu-
tion in the glial pool (Vdil
g¼ 0.23 0.05 mmol/g/min)
due to glial-speciﬁc substrates. CMRglc(ox)
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Figure 3. (a) 13C MRS in vivo spectrum representative of typical data acquired at steady state (3.5 h after the bolus; SNR¼ 24) for
92min in the selected VOI (Figure 2(c)). (b) Multiplet resolution reached at the positions C4 and C3 of Glu and Gln. Doublet and
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(0.38 0.02mmol/g/min) was determined as
(VTCA
nþVTCAgþVPC)/2.
To determine the total CMRglc independently from
13C MRS experiments, we used 18FDG PET.
Speciﬁcally, CMRglc rates in mice brain were deter-
mined by metabolic modeling of 18FDG uptake with
Patlak graphical analysis, dynamically detected in a
group of six mice. Data were quantiﬁed in a voxel cor-
responding to the one used for 13C MRS located in the
mid brain (Figure 5(b)). Examination of linearity in
Patlak plots between 5 and 27min from the injection
led to quantiﬁcation of CMRglc for each animal. R
2
values (0.92–0.99) were examined to evaluate the good-
ness of the ﬁt in the selected time frame. Averaging of
CMRglc over the entire group resulted in a global value
of 0.4 0.1mmol/g/min (mean SD).
Discussion
In the present study, direct detection 13C MRS spectra
were applied from the mouse brain to quantify com-
partmentalized metabolism between neurons and glial
Figure 4. Fractional enrichment curves of Glu and Gln at the position C4, C3, and C2 and Asp C3 as fitted to the neuro-glial
compartmental model (Figure 1(a)). The black solid line represents the best fit as obtained by least square fitting. Dashed lines
represent SD range determined from MC simulation for each experimental curve.
Table 1. Metabolic fluxes estimated in the mouse brain in vivo.
Flux Vg VTCA
n VPC Vx VNT Vout Vdil
g CMRglc(ox)
Mean SD
(mmol/g/min)
0.16 0.03 0.56 0.03 0.041 0.003 0.18 0.02 0.084 0.008 0.20 0.02 0.23 0.05 0.38 0.02
Note: Metabolic fluxes (expressed in mmol/g/min) determined from metabolic modeling of experimental data, based on the scheme shown in Figure 1.
Errors express SD derived from MC simulation with a set of N¼ 300 artificial set of curves for Glu, Gln, and Asp. CMRglc(ox) is calculated as
(VTCA
nþVTCAgþVPC)/2. VTCAn: rate of neuronal TCA cycle; Vg: rate of glial TCA cycle; VPC: pyruvate carboxylase rate; Vx: transmitochondrial
flux rate; VNT: apparent rate of glutamatergic neurotransmission.
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cells. Monte Carlo simulation showed that metabolic
rates were precisely determined, including the ﬂuxes
speciﬁc to the glial compartment (maximal error of
19% on Vg).
The high spectral quality attained was achieved by
integrating state of the art 13C direct detection9 and
shimming techniques16 at ultra-high ﬁeld (14.1 Tesla),
combined with the use of an optimized homemade
1H-13C surface coil. The excellent sensitivity achieved
in an exceptionally small volume (i.e. 112 mL,
Figure 2(c)) allowed separate detection of three ali-
phatic carbons of Glu and Gln (C4, C3, and C2) up
to 13C-13C multiplet resolution (Figure 3(b)) as well as
the measurement of a wide range of brain metabolites
linked to glucose metabolism in the brain, as
Asp, GABA, NAA, Ala, and Lac. All peaks were
separately resolved (Figure 3(a)) with the only excep-
tion of GABAC4 and NAAC3 that have very similar
chemical shifts (respectively 40.2 and 40.3 ppm), thus
appearing inevitably overlapped, even at this ﬁeld
strength.
Direct detection technique further allowed separate
detection of Glu and Gln in the position C2 that are
commonly overlapped in indirect 1H-[13C] MRS detec-
tion.7,10,11,28,29 VPC enables de novo synthesis of carbon
skeletons entering the TCA cycle speciﬁcally in the glial
compartment and introduces additional labeling at the
level of Gln C2, while diluting the C3 position. Thus,
the distinct detection of GlnC2 and GluC2 time courses
is of great importance when aiming for robustness in
metabolic modeling of neuro-glial interactions with
minimal assumptions.6,12
The high temporal resolution of the measurements,
i.e. 10.6min (Figure 2), allowed for mathematical mod-
eling of neuro-glial metabolism, based on labelling of
Glu and Gln at the carbon positions C4, C3, and C2
and Asp at the position C3. The measurements were
assessed to be highly reproducible between individual
animals, as seen from the relatively narrow SD intervals
of the group-averaged 13C turnover curves. This was
ascribed to the implementation of the standardized
infusion protocol and reproducible experimental condi-
tions, despite the inaccessibility of plasma glucose level
during infusion.
Metabolic fluxes
The present study represents to our knowledge the ﬁrst
attempt of mathematical modeling of cerebral metab-
olism in mice based on in vivo 13C-labeling experiments
with direct 13C detection. Previous studies4–6,14,15 have
applied similar techniques to the human and rat brain
gaining important insights on cerebral metabolic com-
partmentation, whereas cerebral metabolism in mice
has only been described by ex vivo measurements30 or
by 13C indirect detection11 subsequently analysed by
simpliﬁed one-compartment model of brain metabol-
ism. While indirect detection gave access to real-time
information on the pool size during infusion,11 includ-
ing the input function,11 direct detection reduces the
peak overlap and increases the number of dynamically
detectable metabolites carbon positions. In the present
model, 1H MRS spectra enabled the determination of
metabolites pool size in vivo to derive FE values for
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Figure 5. (a) Example of Patlak graphical analysis on a single 18F-FDG PETexperiment. Linear fit performed between 5 and 27min is
shown with a solid black line. A significant k*4 activity is visible in the last points from a concave inflection of the Patlak plot. (b)
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each metabolite included in the metabolic modeling, by
assuming constant pool size over the experiment.
The obtained neuronal and glial TCA cycle ﬂuxes
were comparable with values from published data in
human and rat brain in vivo as well in the mouse
brain ex vivo (Table 2). Neuronal TCA cycle rate in
the awake human brain at rest averages to
0.7 0.09 mmol/g/min2, while it tends to be lower in
rats and mice (Table 2).
The transmitochondrial exchange ﬂux Vx was com-
parable to VTCA
n
, similar to previous studies.
3,11,6,15,31
This implies that the malate-Asp shuttle is a major
mechanism of label transfer across the mitochondrial
membrane, as discussed previously.3
The metabolic ﬂuxes determined in this study rep-
resent an average over the examined VOI and are thus
expected to be mostly inﬂuenced by metabolic
exchanges in the central part of the brain, mainly
the striatum. VNT can vary considerably through dif-
ferent brain regions and is typically higher in regions
dominated by excitatory synapses (i.e. cortex) charac-
terized by higher rates of glucose oxidation.30
Conversely, the striatum is known for the higher
level of GABA (and therefore likely higher role of
GABAergic neurotransmission) when compared to
cortex, hippocampus and cerebellum30,32 and the
lower rate of excitatory neurotransmission compared
to other regions in the mouse brain.30 Therefore, the
rate VNT found in this study reﬂected this pattern and
was consistent with previously published values in rats
in vivo.8,6 Glial TCA cycle rate and PC rate were in
agreement with previously published values in rats
(Tables 1 and 2), with VPC being one order of magni-
tude smaller than Vg.
Beyond these observations, metabolic rates could be
dependent on the speciﬁc strain used in the experiment
and possibly from the use of anaesthetics.33,34 However,
a deeper understanding of these aspects is far from
being attained given the limited number of studies
available on the topic.
In our study, the levels of brain Lac (4.3 0.8mmol/
g), enabled the measurement of Lac enrichment turn-
over, as early as 5min after the start of the infusion. 1H
MRS studies of metabolite concentrations in the mouse
brain indicated a higher cerebral Lac concentration in
this species32 compared to rats,35 especially in the stri-
atum, where levels as high as 5 mmol/g were reported in
C57BL/6 mice.32 Given this relatively low concentra-
tion in rats (usually below 2 mmol/g in the rat stri-
atum35), Lac peaks are often barely detectable in 13C
MRS studies under physiological conditions upon infu-
sion of labeled glucose,9,6 whereas a complete time
course was registered in the mouse brain by 13C indirect
detection.11 Therefore, in such experiments, which give
access to dynamic information of the Lac pool size, the
13C Lac signal could in principle be used as input func-
tion of the mathematical modeling, as previously
demonstrated11. However, in 13C direct detection
Table 2. Review of the previously published values of metabolic fluxes (mmol/g/min SD).
Metabolic flux quantification from animal and human 13C MRS experiments in resting brain
Reference Species VTCA
n VTCA Vg Vx VNT VPC
40 Rat – 0.46 0.12 – – – –
10 Rat 0.79 0.15a
0.20 0.11b
– 5% VTCA
n c 12.4 4.5b
6.1 3.3c
0.31 0.07a
0.02 0.04b
0.096c
6 Rat 0.46 0.01 – 0.21 0.02 0.99 0.12d 0.10 0.01 0.067 0.004
8 Rat 0.37 0.06 – 0.27 0.02 0.46 0.05d 0.15 0.01 0.087 0.012
2,e Human 0.70 0.09 0.69 0.06 0.09 0.04 – 0.26 0.08 0.06 0.03
11 Mousef – 1.05 0.04 – 0.48 0.02 0.20 0.02 –
30 Mouseg 0.75 0.05 0.83 0.07 0.02 0.04 99.96h 0.18 0.01 0.06 0.03
aGrey matter, glial TCA cycle fixed at 5%VTCA
n, VPC fixed at 0.096 mmol/g/min.
bWhite matter, glial TCA cycle fixed at 5%VTCA
n, VPC fixed at 0.096mmol/g/min.
cFixed values or modeling constraint.
dTransmitochondrial flux between 2OG and Glu in neurons.
eMean and SD from published results in 13C MRS experiment in resting awake human subjects in midline occipital/parietal lobe.
fSpectra acquired in the cortex and striatum, VNT was set to exchange rate between Glu and Gln (Vgln).
gAnalysis of brain extracts from the striatum; three-compartment model is assumed, distinguishing between GABAergic and glutamatergic neuro-
transmission (VNT refers to glutamatergic neurotransmission).
hIterated values in the modeling procedure.
Note: Fluxes are quantified from 13C in vivo experiments in humans, monkeys, rats, and mice. Since available published metabolic fluxes quantified
in vivo in mice are limited, values from mice extracts were included.30 Results are derived from the whole brain if not stated otherwise.
TCA: tricarboxylic acid; VTCA
n: rate of neuronal TCA cycle; VTCA¼VTCAnþVgþVPC: average of TCA cycle rates among neurons and glia; Vg: rate of
glial TCA cycle; VPC: pyruvate carboxylase rate; Vx: transmitochondrial flux rate; VNT: apparent rate of glutamatergic neurotransmission.
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studies, it is generally not recommended to determine
dynamically the Lac FE curve by assuming a constant
pool size for Lac, since volatile anaesthetics36,37 and
nearly hyperglycemic plasma concentrations of glucose
could induce ﬂuctuations of total Lac concentration
over the course of the experiment and would similarly
inﬂuence Ala. Increasing pool size of the measured
metabolites does not represent an obstacle to the meas-
urement of metabolic ﬂuxes, as non-steady-state regime
can be taken into account in the modeling when real-
time information on metabolite pool size is
accessible.8,11
CMRglc determined by
18FDG PET experiments
Total cerebral glucose consumption was evaluated by
simpliﬁed 18FDG kinetic modeling: the linear regression
method applied in Patlak plots for each animal enabled
the determination of the CMRglc in the VOI matched to
that of 13C MRS, under the fundamental assumption of
irreversible FDG-6P kinetics. Patlak graphical ana-
lysis23 is advantageous in evaluating the net glucose
uptake by the brain given the simplicity of the linear
regression method when separate information on the
transport of FDG to the cellular compartment and its
phosphorylation are not necessary. The temporal range
examined was ﬁxed between 5 and 27min, similar to
previously published procedures in mice.25,27 The ﬁrst
few minutes are in fact inﬂuenced by equilibration
between plasma and tissue FDG, while the last time
point included was set to be before 30min in order to
minimize the inﬂuence of k*4 (dephosphorylation of
FDG-6P). FDG-6P reaches typically a plateau 20min
after FDG bolus injection, resulting in a non-negligible
eﬀect of dephosphorylation mostly between 30min and
the end of the experiments.25–27 The eﬀect of a non-
negligible dephosphatase activity was discernible from
the decline of the Patlak curve in the four time points
corresponding to 30 to 50min (Figure 5(a)).
Linear relationships were established in the afore-
mentioned time frames as justiﬁed from R2 values for
each linear ﬁt (0.92–0.99). Reported values and their
variability for CMRglc in the brain were comparable
to other FDG PET studies in mice under
isoﬂurane.26,27,38,39
The value of CMRglc(ox) derived from the amino
acids turnover using 13C MRS (0.38 0.02 mmol/g/
min) is comparable to CMRglc quantiﬁed from PET
experiments. However, a slightly higher glucose metab-
olism measured by 18FDG PET is consistent, given that
glucose can be in part metabolized by glycolysis to lac-
tate and to a smaller extent to glycogen (18FDG PET
measures CMRglc(total)).
For the present study, we conclude that cerebral
brain metabolism can be assessed in vivo in mice with
direct 13C MR spectroscopy at 14.1 Tesla. Given the
high spectral quality obtained in the chosen volume of
detection (112mL), we expect that suﬃcient SNR could
be obtained in the near future in volumes as small as
60 mL for the detection of C4, C3, and C2 resonances of
Glu and Gln, giving access to the detection of regional
glucose metabolism in astrocytes and neurons. The FE
time courses available from those labeled metabolites
allowed us for the ﬁrst time to obtain a complete two-
compartmental description of brain energy metabolism
in mice.
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